Sunshine Biopharma Launches a New Generic Prescription Drug
Sunshine Biopharma (NASDAQ:SBFM) announced that its Canadian subsidiary, Nora Pharma, has launched Bilastine, a generic version of Blexten®, in Canada. The drug, available in 20 mg tablets, is used for allergy symptom relief, specifically treating allergic rhinitis and urticaria (hives).
The global Bilastine market was valued at $1.3 billion in 2023 and is projected to reach $2.3 billion by 2030, with a 6.6% CAGR. This marks the company's fourth new product launch this year in the Canadian generic drugs market, which was valued at $9.7 billion in 2023 and is expected to reach $19.2 billion by 2032.
Sunshine Biopharma (NASDAQ:SBFM) ha annunciato che la sua filiale canadese, Nora Pharma, ha lanciato Bilastine, una versione generica di Blexten®, in Canada. Il farmaco, disponibile in compresse da 20 mg, è utilizzato per il sollievo dai sintomi allergici, in particolare per trattare la rinite allergica e l'orticaria (pomfi).
Il mercato globale di Bilastine è stato valutato 1,3 miliardi di dollari nel 2023 e si prevede raggiungerà 2,3 miliardi di dollari entro il 2030, con un tasso di crescita annuale del 6,6%. Questo segna il quarto lancio di un nuovo prodotto quest'anno nel mercato canadese dei farmaci generici, che è stato valutato 9,7 miliardi di dollari nel 2023 e ci si aspetta raggiunga 19,2 miliardi di dollari entro il 2032.
Sunshine Biopharma (NASDAQ:SBFM) anunció que su subsidiaria canadiense, Nora Pharma, ha lanzado Bilastine, una versión genérica de Blexten®, en Canadá. El medicamento, disponible en tabletas de 20 mg, se utiliza para el alivio de los síntomas alérgicos, particularmente para tratar la rinitis alérgica y la urticaria (ronchas).
El mercado global de Bilastine fue valorado en 1.3 mil millones de dólares en 2023 y se proyecta que alcanzará 2.3 mil millones de dólares para 2030, con una tasa de crecimiento anual compuesta del 6.6%. Este es el cuarto lanzamiento de un nuevo producto este año en el mercado canadiense de medicamentos genéricos, que fue valorado en 9.7 mil millones de dólares en 2023 y se espera que alcance 19.2 mil millones de dólares para 2032.
선샤인 바이오파마 (NASDAQ:SBFM)는 캐나다 자회사인 노라 제약이 빌라스틴을 출시했다고 발표했습니다. 이는 캐나다에서 판매되는 블렉스텐®의 일반 의약품 버전입니다. 이 약물은 20mg 태블릿 형태로 제공되며, 알레르기 비염과 두드러기(두드러기) 치료를 위해 알레르기 증상을 완화하는 데 사용됩니다.
글로벌 빌라스틴 시장은 2023년에 13억 달러로 평가되었으며, 2030년까지 23억 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 6.6%입니다. 이는 올해 캐나다 일반 의약품 시장에서 회사가 출시한 네 번째 신제품으로, 해당 시장의 가치는 2023년에 97억 달러로 평가되었으며, 2032년까지 192억 달러에 이를 것으로 예상됩니다.
Sunshine Biopharma (NASDAQ:SBFM) a annoncé que sa filiale canadienne, Nora Pharma, a lancé Bilastine, une version générique de Blexten®, au Canada. Le médicament, disponible sous forme de comprimés de 20 mg, est utilisé pour soulager les symptômes allergiques, en particulier pour traiter la rhinite allergique et l'urticaire (réaction cutanée).
Le marché mondial de la Bilastine était évalué à 1,3 milliard de dollars en 2023 et devrait atteindre 2,3 milliards de dollars d'ici 2030, avec un taux de croissance annuel de 6,6%. Cela marque le quatrième lancement de produit nouveau de l'entreprise cette année sur le marché canadien des médicaments génériques, qui était évalué à 9,7 milliards de dollars en 2023 et devrait atteindre 19,2 milliards de dollars d'ici 2032.
Sunshine Biopharma (NASDAQ:SBFM) gab bekannt, dass ihre kanadische Tochtergesellschaft, Nora Pharma, Bilastine, eine generische Version von Blexten®, in Kanada auf den Markt gebracht hat. Das Medikament, das in 20 mg Tabletten erhältlich ist, wird zur Linderung von Allergiesymptomen eingesetzt, insbesondere zur Behandlung von allergischer Rhinitis und Urtikaria (Nesselsucht).
Der globale Bilastine-Markt wurde 2023 auf 1,3 Milliarden US-Dollar geschätzt und wird voraussichtlich bis 2030 auf 2,3 Milliarden US-Dollar wachsen, mit einer jährlichen Wachstumsrate von 6,6%. Dies markiert die vierte Produkteinführung des Unternehmens in diesem Jahr auf dem kanadischen Markt für Generika, der 2023 auf 9,7 Milliarden US-Dollar geschätzt wurde und bis 2032 auf 19,2 Milliarden US-Dollar anwachsen soll.
- Launch of new generic drug Bilastine in the Canadian market
- Fourth new product launch in 2023, showing consistent product expansion
- Entering a growing global Bilastine market valued at $1.3 billion
- Targeting Canadian generic drugs market with $9.7 billion valuation
- None.
Insights
The launch of Bilastine represents a strategic expansion in Sunshine Biopharma's generic drug portfolio. With the global Bilastine market valued at
For a micro-cap company with a market cap of just
The timing and market positioning of Bilastine's launch is strategic. The growing prevalence of allergic conditions and increased healthcare spending create favorable market conditions. Second-generation antihistamines like Bilastine typically have fewer side effects than first-generation alternatives, making them preferred choices for long-term use. The drug's dual indication for both allergic rhinitis and urticaria expands its potential user base.
The Canadian market entry with a generic version of Blexten® could drive market penetration through competitive pricing while maintaining profitable margins. Generic drugs typically capture significant market share from branded counterparts, especially in healthcare systems focused on cost management.
FORT LAUDERDALE, FL / ACCESSWIRE / December 4, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug in Canada.
The newly launched drug is Bilastine, a generic version of Blexten®. Bilastine is indicated for the relief of allergy symptoms. Nora Pharma's Bilastine is available for the Canadian market in 20 mg tablets.
The market size of Bilastine in Canada is part of the broader global Bilastine market, which, according to Verified Market Reports, was valued at
Bilastine is a second-generation antihistamine specifically used for the treatment of allergic rhinitis and urticaria. The latter is commonly known as hives. It is a skin condition characterized by red, itchy welts that can vary in size and shape. Urticaria is often caused by an allergic reaction to certain foods, medications, or other substances. The condition can be acute, lasting for a few days or weeks, or chronic, persisting for months or even years. The demand for effective antihistamines like Bilastine continues to grow due to rising awareness of allergic conditions and increasing healthcare expenditure globally.
"This is the fourth new product we have introduced this year. We are expanding our footprint in the Canadian generic drugs market, which was valued at
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 64 generic prescription drugs on the market in Canada and 30 additional drugs scheduled to be launched in 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma, Inc.
View the original press release on accesswire.com
FAQ
What new drug did Sunshine Biopharma (SBFM) launch in December 2023?
What is the market size for Bilastine according to Sunshine Biopharma (SBFM)?
How many new products has Sunshine Biopharma (SBFM) launched in 2023?
What is the projected value of the Canadian generic drugs market that SBFM is targeting?
